Perspective Therapeutics (NYSE:CATX) Rating Lowered to “Neutral” at Bank of America

Perspective Therapeutics (NYSE:CATX) was downgraded by investment analysts at Bank of America from a “buy” rating to a “neutral” rating in a research report issued on Monday, MarketBeat Ratings reports. They presently have a $5.00 target price on the stock, down from their previous target price of $24.00. Bank of America‘s target price points to a potential upside of 14.42% from the company’s previous close.

Several other research analysts have also recently weighed in on CATX. Oppenheimer lowered their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective (down from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Truist Financial started coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective on the stock. UBS Group started coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Royal Bank of Canada decreased their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a report on Friday, August 16th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Perspective Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $15.14.

Perspective Therapeutics Stock Performance

CATX stock opened at $4.37 on Monday. The business has a 50-day moving average price of $11.15. Perspective Therapeutics has a 12-month low of $2.28 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. As a group, analysts expect that Perspective Therapeutics will post -0.86 earnings per share for the current year.

Insider Buying and Selling at Perspective Therapeutics

In related news, CEO Johan M. Spoor acquired 14,500 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were acquired at an average price of $3.78 per share, with a total value of $54,810.00. Following the completion of the transaction, the chief executive officer now owns 152,072 shares of the company’s stock, valued at $574,832.16. The trade was a 10.54 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.52% of the stock is owned by corporate insiders.

Institutional Trading of Perspective Therapeutics

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after acquiring an additional 4,566,356 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Perspective Therapeutics during the first quarter worth $15,511,000. FMR LLC increased its position in shares of Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after acquiring an additional 5,370,392 shares during the period. State Street Corp increased its position in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the period. Finally, Nicholson Wealth Management Group LLC purchased a new stake in shares of Perspective Therapeutics during the third quarter worth $21,390,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.